Erin Morella, MD
Pain Medicine · Vestavia, ALNPI 1336403716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.
Across 195 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$680
- Scilex Pharmaceuticals Inc.$507
- Collegium Pharmaceutical, Inc.$306
- Amgen$305
- Pfizer$267
- Assertio Therapeutics, Inc.$108
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $680 |
| Scilex Pharmaceuticals Inc. | 32 | $507 |
| Collegium Pharmaceutical, Inc. | 18 | $306 |
| Amgen(2 entities) | 15 | $305 |
| Pfizer | 15 | $267 |
| Assertio Therapeutics, Inc. | 6 | $108 |
| Lilly USA, LLC | 6 | $95 |
| Abbott | 4 | $83 |
| Spinal Simplicity, LLC | 4 | $70 |
| Boston Scientific | 4 | $67 |
| Novartis | 4 | $60 |
| Supernus Pharmaceuticals, Inc. | 1 | $59 |
| Biotronik NRO, Inc. | 2 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Medtronic(2 entities) | 3 | $54 |
| Zyla Life Sciences, Inc. | 3 | $52 |
| SPR Therapeutics, Inc | 6 | $52 |
| Redhill Biopharma Inc. | 3 | $44 |
| Nevro Corp. | 2 | $43 |
| Almatica Pharma LLC | 2 | $42 |
| Si-bone, Inc. | 2 | $36 |
| Azurity Pharmaceuticals, Inc. | 2 | $35 |
| MDD US Operations, LLC | 2 | $33 |
| Averitas Pharma Inc. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| MML US, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $20 |
| Atland Pharmaceuticals, LLC | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Epimed International, Inc | 1 | $11 |
How this compares
$3,349 in reported general payments places this provider in the 70th percentile of 77 pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,032 | $68,321 |
| BelbucaBuprenorphine Hcl | 88 | $56,424 |
| ZtlidoLidocaine | 43 | $47,547 |
| Buprenorphine | 174 | $47,211 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,629 | $44,208 |
| Lidocaine | 174 | $41,272 |
| Xtampza ErOxycodone Myristate | 70 | $38,630 |
| Gabapentin | 1,601 | $24,999 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 111 | $21,918 |
| UbrelvyUbrogepant | 14 | $18,001 |
| Pregabalin | 699 | $13,742 |
| OxycontinOxycodone Hcl | 24 | $13,225 |
| MovantikNaloxegol Oxalate | 28 | $11,158 |
| NucyntaTapentadol Hcl | 12 | $7,275 |
| Duloxetine Hcl | 326 | $5,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $306 | $102,329170 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $507 | $47,54743 claims |
| AbbVieUbrelvy | $680 | $18,00114 claims |
| Redhill Biopharma Inc.Movantik | $44 | $11,15828 claims |
| Upsher-smith Laboratories LLCTopiramate | $24 | $1,41528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 pain medicine providers in Alabama.
Other pain medicine in Vestavia
- Rachel RobertsVestavia$3K
- Robert ThomasVestavia$2K
- Christopher PaulBirmingham$64K
- Michael CosgroveHuntsville$25K
- Ron PitkanenMountain Brk$16K
- Elliott PenningtonDaphne$15K
- James ThackerHuntsville$13K
- Grant StoneMobile$11K
- Hayden HundleyDothan$11K
- Hugh MaddoxAnniston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.